Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Frederick L LockeDavid B MiklosCaron A JacobsonMiguel-Angel PeralesMarie-José KerstenOlalekan O OluwoleArmin GhobadiAaron P RapoportJoseph McGuirkJohn M PagelJavier MuñozUmar FarooqTom van MeertenPatrick M ReaganAnna SuredaIan W FlinnPeter VandenbergheKevin W SongMichael DickinsonMonique C MinnemaPeter A RiedellLori A LeslieSridhar ChagantiYin YangSimone FilostoJina ShahMarco SchuppChristina ToPaul ChengLeo I GordonJason R Westinnull nullPublished in: The New England journal of medicine (2021)
Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).